Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CRM Announces European Launch of World's Smallest 1.5T & 3T MRI Conditional Pacemaker Portfolio*

[2019-01-08] 

Clamart, France – January 03rd, 2019 - MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce the European launch of its next generation MR-conditional transvenous pacing systems. This launch sees the introduction of three new pacemaker families: Eno™, Teo™ and Oto™.
 
All models in the three new pacemaker families are full-body MR-conditional, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines without any exclusion zones, permitting physicians to perform MRI scans on all areas of the body.
 
In addition, the new products Eno™, Teo™ and Oto™ feature AutoMRI™ technology, enabling implanted pacemakers to automatically switch in and out of MRI mode upon detection of the MR field. AutoMRI™ ensures appropriate pacemaker operation during the scan and allows patients to benefit from optimal pacing settings right up to and just after the scan.
 
The new pacemaker portfolio also features :
 
- Phi Intelligence™: a permanent adaptive pacing strategy that responds to all levels of patient activity, day and night, evolving and learning with the patient’s conditions in order to mimic the natural way the heart works, minimizing artificial intervention.
 
- AF Risk Management™: a unique combination of features that helps physicians to accurately detect Atrial Fibrillation (AF), minimize ventricular pacing and screen for sleep apnea so as to protect patients from developing AF.
 
- Preset Fit™: a set of capabilities including precision programming calibrated through clinical experience and designed to facilitate the implant procedure and device follow up.
 
"Our customers have been very pleased with the technology and therapeutic functions we have introduced in our pacemakers year after year," commented Benoît Clinchamps, President of MicroPort® CRM. "Augmented with the capability to undergo 3T MRI scans, the introduction of these three new pacemaker families builds on our strengths, offering state-of-the-art pacing therapies."
 
*Transvenous cardiac pacing systems.

 

About MicroPort® CRM
 
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort Scientific Corporation.
 
For more information visit www.crm.microport.com

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:MicroPort® CRM Announces European Launch of New Tablet Programmer for Implantable Cardiac Devices
[Next]:Mr. Noboru Shimizu Joined MicroPort® CRM as Vice-President, Country Manager Japan, and Head of Commercial Operations of MicroPort® CRM Japan Co. Ltd.